Aytu Biopharma, Inc. (AYTU)
2.14
+0.02
(+0.94%)
USD |
NASDAQ |
Sep 21, 16:00
2.14
0.00 (0.00%)
After-Hours: 20:00
Aytu Biopharma Gross Profit Margin (Quarterly) : 55.10% for March 31, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 55.10% |
| December 31, 2025 | 59.99% |
| September 30, 2025 | 62.95% |
| June 30, 2025 | 61.66% |
| March 31, 2025 | 64.42% |
| December 31, 2024 | 60.82% |
| September 30, 2024 | 66.76% |
| June 30, 2024 | 69.42% |
| March 31, 2024 | 67.32% |
| December 31, 2023 | 72.99% |
| September 30, 2023 | 67.99% |
| June 30, 2023 | 56.52% |
| March 31, 2023 | 50.79% |
| December 31, 2022 | 61.25% |
| September 30, 2022 | 60.88% |
| June 30, 2022 | 49.34% |
| March 31, 2022 | 48.04% |
| December 31, 2021 | 48.60% |
| September 30, 2021 | 51.89% |
| June 30, 2021 | 39.58% |
| March 31, 2021 | -13.24% |
| December 31, 2020 | 49.94% |
| September 30, 2020 | 60.03% |
| June 30, 2020 | 56.89% |
| March 31, 2020 | 58.69% |
| Date | Value |
|---|---|
| December 31, 2019 | 50.88% |
| September 30, 2019 | 33.96% |
| June 30, 2019 | 28.65% |
| March 31, 2019 | 49.87% |
| December 31, 2018 | 40.99% |
| September 30, 2018 | 39.73% |
| June 30, 2018 | 31.09% |
| March 31, 2018 | -150.9% |
| December 31, 2017 | 26.82% |
| September 30, 2017 | 37.47% |
| June 30, 2017 | 10.59% |
| March 31, 2017 | 14.78% |
| December 31, 2016 | -24.44% |
| September 30, 2016 | 9.89% |
| June 30, 2016 | 23.73% |
| March 31, 2016 | 31.26% |
| December 31, 2015 | 24.85% |
| September 30, 2015 | 65.88% |
| March 31, 2015 | 0.00% |
| February 28, 2015 | |
| November 30, 2014 | |
| August 31, 2014 | |
| May 31, 2014 | 0.00% |
| February 28, 2014 | |
| November 30, 2013 |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 54.97% |
| Corcept Therapeutics, Inc. | 98.41% |
| Veru, Inc. | -- |
| Johnson & Johnson | 68.73% |
| Eli Lilly & Co. | 85.78% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -135.0% |
| Return on Assets | -28.09% |
| Return on Invested Capital | -69.55% |
| Profit Margin (Quarterly) | -45.27% |
| Operating Margin (Quarterly) | -32.75% |
| Return on Net Operating Assets | -37.48% |